[1] METZLER I, BAYNE D, CHANG H, et al. Challenges facing the urologist in low- and middle-income countries[J]. World J Urol, 2020, 38(11):2987-2994. doi:  10.1007/s00345-020-03101-6
[2] WANG W Y, GUO Y W, ZHANG D X, et al. The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys[J]. Sci Rep, 2015, 5:13546. doi:  10.1038/srep13546
[3] COLLABORATORS G 2 B P H. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Healthy Longev, 2022, 3(11):e754-e776. doi:  10.1016/S2666-7568(22)00213-6
[4] 宋爽, 蒋运兰, 李滔, 等. 中国成年男性良性前列腺增生发生率的Meta分析[J]. 预防医学情报杂志, 2024: 1–10.
[5] XU X F, LIU G X, GUO Y S, et al. Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019[J]. Am J Mens Health, 2021, 15(4): 15579883211036786.
[6] 罗丽莎, 栾航航, 朱聪, 等. 1990—2019年中国、日本与韩国的良性前列腺增生疾病负担比较[J]. 现代泌尿外科杂志, 2023, 28(6):506-512. doi:  10.3969/j.issn.1009-8291.2023.06.010
[7] 王晓明, 蒲春晓, 韩平. 良性前列腺增生的药物治疗新进展[J]. 现代泌尿外科杂志, 2015, 20(6):439-443,444. doi:  10.3969/j.issn.1009-8291.2015.06.022
[8] 逄瑷博, 张春燕, 凌存保, 等. 5-α还原酶抑制剂联合治疗良性前列腺增生的研究进展[J]. 武警医学, 2023, 34(1):78-82. doi:  10.3969/j.issn.1004-3594.2023.01.022
[9] 王东文, 原小斌. 良性前列腺增生药物治疗的昨天、今天、明天[J]. 现代泌尿外科杂志, 2020, 25(2):105-108. doi:  10.3969/j.issn.1009-8291.2020.02.004
[10] 那彦群, 叶章群, 孙光. 中国泌尿外科疾病诊断治疗指南: 2011版[M]. 北京: 人民卫生出版社, 2011.

LinkOut.
[11] 国家医保局, 人力资源社会保障部. 国家基本医疗保险、工伤保险和生育保险药品目录(2023年)[EB/OL]. [2023-12-31]. https://www.nhsa.gov.cn/art/2023/12/13/art_104_11673.html.
[12] 柯子立, 姚荣成, 陈志强, 等. 多沙唑嗪治疗轻、中度原发性高血压有效性和安全性的Meta分析[J]. 昆明医科大学学报, 2015, 1(7):28-32,39. doi:  10.3969/j.issn.1003-4706.2015.07.007
[13] NICKEL J C, GILLING P, TAMMELA T L, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)[J]. BJU Int, 2011, 108(3):388-394. doi:  10.1111/j.1464-410X.2011.10195.x
[14] JUNG J H, KIM J, MACDONALD R, et al. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia[J]. Cochrane Database Syst Rev, 2017, 11(11):CD012615.